# EDGAR Filing Document

**Accession Number:** 0001910456
**File Stem:** 0000902664-25-004537
**Filing Date:** 2025-10
**Character Count:** 15043
**Document Hash:** 608111ec9301c5a52dc87732383bc85d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000902664-25-004537.hdr.sgml**: 20251023

**ACCESSION NUMBER**: 0000902664-25-004537

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20251023

**DATE AS OF CHANGE**: 20251023

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuphoria Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001191070
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93208
- **FILM NUMBER:** 251414053

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 781-439-5551

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIONOMICS LIMITED/FI
- **DATE OF NAME CHANGE:** 20020920
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lynx1 Capital Management LP
- **CENTRAL INDEX KEY:** 0001910456

**ORGANIZATION NAME:**
- **EIN:** 851134656
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231
- **LEGAL ENTITY IDENTIFIER:** 5493003YH8Q5SHT17216

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** D81 CALLE C
- **STREET 2:** SUITE 301 PMB 1202
- **CITY:** DORADO
- **PROVINCE COUNTRY:** PR
- **ZIP:** 00646
- **BUSINESS PHONE:** 703-963-7214

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** D81 CALLE C
- **STREET 2:** SUITE 301 PMB 1202
- **CITY:** DORADO
- **PROVINCE COUNTRY:** PR
- **ZIP:** 00646

## Ex-99

**SCHEDULE A**

**Transactions of the COMPANY**

**DURING THE PAST SIXTY (60) DAYS**

The following table sets forth all transactions in the shares of Common Stock during the past sixty (60) days by the Reporting Persons. All such transactions were effected in the open market through brokers and the price per share excludes commissions. The shares of Common Stock were purchased or sold in multiple transactions at prices indicated in the column Price Per Share ($). Where a price range is provided in the column Price Range ($), the price reported in that row's Price Per Share ($) column is a weighted average price. The shares of Common Stock were purchased or sold in multiple transactions at prices between the price ranges indicated in the Price Range ($) column. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock purchased or sold at each separate price.

---

| | | | |
|:---|:---|:---|:---|
| **<u>Trade Date</u>** | **<u>Shares Purchased (Sold)</u>** | **<u>Price per Share ($)</u>** | **<u>Price Range ($)</u>** |
| 08/27/2025 | (1926) | 10.6700 |  |
| 09/17/2025 | (1000) | 11.0570 | 11.0000 - 11.0700 |
| 09/18/2025 | (900) | 10.6322 | 10.5000 - 10.9000 |
| 09/19/2025 | (7950) | 10.1517 | 10.1000 - 10.2500 |
| 09/22/2025 | (1841) | 10.1978 | 10.1000 - 10.2250 |
| 09/23/2025 | (20511) | 10.8079 | 10.4000 - 11.3850 |
| 09/23/2025 | (6335) | 11.5486 | 11.4000 - 12.0100 |
| 09/24/2025 | (3363) | 11.1836 | 11.0000 - 11.6800 |
| 10/20/2025 | 3366 | 4.9500 |  |
| 10/21/2025 | 869982 | 5.0883 | 4.7900 – 5.2000 |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

**<u>Joint Filing Agreement, dated October 23, 2025</u>**

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to such statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the other except to the extent that he or it knows that such information is inaccurate.

DATE: October 23, 2025

---

| |
|:---|
| LYNX1 CAPITAL MANAGEMENT LP<br> By: Lynx1 Capital Management GP LLC, its general partner |
| By: /s/ Weston Nichols |
| Name: Weston Nichols |
| Title: Sole Member |
| /s/ Weston Nichols |
| WESTON NICHOLS |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Neuphoria Therapeutics Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.00001 per share**

*(Title of Class of Securities)*

**64136E102**

*(CUSIP Number)*

**Lynx1 Capital Management LP**<br>D81 Calle C, STE 301, PMB 1202<br>Dorado PR 00646-2051<br>929-888-7476

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/21/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **64136E102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Lynx1 Capital Management LP** | Name of reporting person<br>**Lynx1 Capital Management LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**875328.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**875328.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**875328.00** | Aggregate amount beneficially owned by each reporting person<br>**875328.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**37.1%** | Percent of class represented by amount in Row (11)<br>**37.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **64136E102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Weston Nichols** | Name of reporting person<br>**Weston Nichols** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**875328.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**875328.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**875328.00** | Aggregate amount beneficially owned by each reporting person<br>**875328.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**37.1%** | Percent of class represented by amount in Row (11)<br>**37.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.00001 per share

**(b) Name of Issuer:**
Neuphoria Therapeutics Inc.

**(c) Address of Issuer's Principal Executive Offices:**
100 SUMMIT DR, BURLINGTON, MA, 01803

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the securities reported herein because they believe the securities are undervalued and represent an attractive investment opportunity.

The Reporting Persons may communicate with the Company's management and board of directors (the "Board") about, and may enter into negotiations and agreements with them regarding, among other things, the Company's operations, management, Board composition, ownership, capital or corporate structure, sale transactions, dividend and buyback policies, strategy and plans, including any transactions involving the Company or certain of the Company's businesses or assets, including transactions in which the Reporting Persons may seek to participate and potentially engage in, and may communicate with other shareholders or third parties, regarding the Company and the foregoing, and the exploration and/or development of  plans and/or proposals (whether preliminary or final) with respect to the foregoing. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Persons may change its intentions with respect to any and all matters referred to in this Item 4. The Reporting Persons may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such transactions.

The Reporting Persons intend to review their investment in the Company on a continuing basis and depending upon various factors, including without limitation, the Company's financial position and strategic direction, the outcome of any discussions referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Company at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor (i) to increase or decrease their position in the Company through, among other things, the purchase or sale of securities of the Company, including through transactions involving shares of Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Company in the open market or in private transactions, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) to enter into transactions that increase or decrease their economic exposure to the shares of Common Stock without affecting their beneficial ownership of the shares of Common Stock or adjust their exposure to the shares of Common Stock in ways that would affect their beneficial ownership of the shares of Common Stock. In addition, the Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of shares of Common Stock beneficially owned by the Reporting Persons. The aggregate percentage of shares of Common Stock reported to be beneficially owned by the Reporting Persons is based upon 2,357,613 shares of Common Stock outstanding as of September 29, 2025, as reported in the Company's Annual Report on Form 10-K for the fiscal ended June 30, 2025, filed with the Securities and Exchange Commission (the "SEC") on September 29, 2025.

**(b)**
See rows (7) through (10) of the cover page to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Persons have the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
All transactions in the shares of Common Stock effected by the Reporting Persons during the past sixty (60) days, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Except as set forth herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Company, including any class of the Company's securities used as a reference security, in connection with any of the following: call options, put options, security-based swaps or any other derivative securities, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Lynx1 Capital Management LP

**Signature:** /s/ Weston Nichols

**Name/Title:** By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member

**Date:** 10/23/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Weston Nichols

**Signature:** /s/ Weston Nichols

**Name/Title:** Weston Nichols, individually

**Date:** 10/23/2025